Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Primary Breast Cancer
NCT00156312Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2003
- Primary completion
- May 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and capecitabine in breast cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Thymidine Phosphorylase expression levels and Clinical or Pathologic Response Rate. Started Jul 2003; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00156312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156312.